Talazoparib (Talzenna®) in combination with enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update September 2024

Rothschedl, E. and Grössmann, N. (2023): Talazoparib (Talzenna®) in combination with enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update September 2024. Fact Sheet Nr. 161.

[thumbnail of Fact Sheet Nr.161_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
146kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WJ Urogenital system > WJ 700-875 Male genitalia
Language:	English
Series Name:	Fact Sheet Nr. 161
Deposited on:	18 Dec 2023 16:07
Last Modified:	25 Sep 2024 14:31

Repository Staff Only: item control page